Woolley Pau wins Galderma UK account
pharmafile | May 21, 2010 | News story | Medical Communications | Galderma, Woolley Pau
Dermatology specialist Galderma UK has appointed advertising agency Woolley Pau to work on a number of product launches.
The agency has not yet set to work on the pipeline products, but its client services director Sue says their launches were “not that far away”.
Woolley Pau has also been hired to work on Galderma’s Curanail (amorolfine), an existing OTC once-weekly treatment for mild fungal nail infections.
Woolley Pau, whose clients include Astellas and Abbott, will develop all the brands’ marketing material for TV, print and for use in pharmacies.
The campaigns will be aimed at users and pharmacists, with the Woolley Pau team comprising three account people and four creatives.
“We can’t yet get into too much detail,” said Sue Samsonov, who is leading the account. “But we will be doing both consumer-focused and professional work.”
The company has already started looking at Curanail, where its relative ease of use as a topical treatment is likely to be emphasised in any marketing material.
Based in Watford, Galderma is part of the L’Oreal empire and had three agencies in for the final pitch.
Established in 1997, Galderma’s £23 million UK arm takes in prescription products, and corrective and aesthetic procedures, as well as OTC brands.
She reports to Galderma marketing director Sandy Richardson, who said: “The team from Woolley Pau responded to our brief in a very robust and challenging manner, presenting some very innovative and thought-provoking initiatives across a range of channels.”
Galderma has manufacturing plants in France, Brazil and Canada – the latter of which is being modernised and expanded.
In February it was announced that the regional government of Québec is contributing 10% of the Canadian $38 million needed for site improvements in Baie-d’Urfé.
The company also has research and development centres in France, the US and Japan.
Adam Hill
Related Content
Galderma launches clinical trials for nemolizumab in systemic sclerosis and chronic pruritus of unknown origin
Galderma has announced the launch of two phase 2 clinical trials evaluating its monoclonal antibody, …
Merck and Galderma breach ABPI code
Merck Serono and Galderma will be named in advertisements as guilty of the most serious …
Galderma earns wrath of PMCPA in unprecedented case
Galderma has sensationally pulled out of the UK’s good conduct pact after the watchdog overseeing …
